Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Average PT from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $55.06.

Several equities research analysts have recently commented on the company. BTIG Research assumed coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Morgan Stanley increased their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Leerink Partners restated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, Guggenheim increased their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st.

Insiders Place Their Bets

In related news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares during the period. Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics in the 3rd quarter worth approximately $61,000. KBC Group NV raised its position in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares in the last quarter. Quarry LP bought a new position in shares of Kymera Therapeutics in the 3rd quarter worth approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares in the last quarter.

Kymera Therapeutics Price Performance

KYMR opened at $44.36 on Thursday. The firm’s fifty day moving average price is $42.63 and its two-hundred day moving average price is $44.73. Kymera Therapeutics has a fifty-two week low of $29.24 and a fifty-two week high of $53.27. The company has a market capitalization of $2.87 billion, a P/E ratio of -18.96 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the prior year, the business earned ($0.90) EPS. Kymera Therapeutics’s revenue for the quarter was down 20.9% compared to the same quarter last year. On average, equities research analysts expect that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.